About Genomics Biomarkers
A measurable DNA and/or RNA characteristic is an indicator of normal biologic processes, pathogenic processes, and/or response to a therapeutic or other interventions. A genomic biomarker can be used for measuring the expression, function, and regulation of a gene. These biomarkers have characteristics of one or more deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA).
Technavio’s analysts forecast the global genomics biomarkers market to grow at a CAGR of 17.59% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global genomics biomarkers market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of genomic biomarkers.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Genomics Biomarkers Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Roche Diagnostics
• Myriad Genetics
• QIAGEN
• Thermo Fisher Scientific
• Bio-Rad Laboratories
Other prominent vendors
• 23andMe
• Aepodia
• Almac Group
• AROS Applied Biotechnology
• DNAVision
• Epigenomics
• Epistem
• Eurofins Scientific
• Foundation Medicine
• Genomic Health
• Liquid Genomics
• New England Biolabs
• OriGene
• US Biomarkers
Market driver
• Genomics biomarker-based personalized medicine
• For a full, detailed list, view our report
Market challenge
• Delay in time from lab to market
• For a full, detailed list, view our report
Market trend
• Expansion of new business models
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Market segmentation by indication
PART 07: Market segmentation by end-user
• Diagnostic and research laboratories
• Hospitals
PART 08: Geographical segmentation
• Genomics biomarkers market in Americas
• Genomics biomarkers market in EMEA
• Genomics biomarkers market in APAC
PART 09: Market drivers
• Increasing low-cost clinical trials in developing countries
• Improving research network infrastructures
• Genomics biomarker-based personalized medicine
PART 10: Impact of drivers
PART 11: Market challenges
• Reproducibility of genomic biomarkers and tests leading to discrepancies
• Delay in time from lab to market
• Reimbursement challenges for genomics biomarkers-based tests
PART 12: Impact of drivers and challenges
PART 13: Market trends
• Improvement in care delivery with advances in genomics technologies
• Expansion of new business models
• Development of affordable genomic biomarkers as diagnostics for tropical diseases
PART 14: Vendor landscape
PART 15: Key vendor analysis
• Roche Diagnostics
• Myriad Genetics
• QIAGEN
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Other prominent vendors
PART 16: Appendix
• List of abbreviations
PART 17: Explore Technavio
List of Exhibits
Exhibit 01: Important DNA and RNA characteristics of a genomic biomarker
Exhibit 02: Product offerings
Exhibit 03: The biomarkers discovery strategies
Exhibit 04: The value chain on genomics biomarkers
Exhibit 05: Global genomics biomarkers overview
Exhibit 06: Global genomics biomarkers market ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Global genomics biomarkers market by indication
Exhibit 09: Market scenario of genomics biomarkers in oncology
Exhibit 10: Market scenario of genomics biomarkers in cardiovascular diseases
Exhibit 11: Market scenario of genomics biomarkers in neurological diseases
Exhibit 12: Global genomics biomarkers market share by end-user
Exhibit 13: Global genomics biomarkers market by geography 2016 (% revenues)
Exhibit 14: Genomics biomarkers market in Americas overview
Exhibit 15: Genomics biomarkers market in Americas ($ billions)
Exhibit 16: Market analysis of genomics biomarkers in Americas
Exhibit 17: Genomics biomarkers market in EMEA overview
Exhibit 18: Genomics biomarkers market in EMEA ($ billions)
Exhibit 19: Market analysis of genomics biomarkers in EMEA
Exhibit 20: Genomics biomarkers market in APAC overview
Exhibit 21: Genomics biomarkers market in APAC ($ millions)
Exhibit 22: Market analysis of genomics biomarkers in APAC
Exhibit 23: Some of the prominent consortia for development of biomarkers
Exhibit 24: Impact of drivers
Exhibit 25: Criteria for acceptable biomarker-based test
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Techniques used in arriving at single-cell biology
Exhibit 28: Trends and innovators in genomic technologies
Exhibit 29: Global genomics biomarkers market competitor rankings 2016
Exhibit 30: Competitive structure analysis of global genomics biomarkers market 2016
Exhibit 31: Global genomics biomarkers market-competitive landscape
Exhibit 32: Game-changing strategies for market participants
Exhibit 33: Roche Diagnostics strength assessment
Exhibit 34: Roche Diagnostics strategy assessment
Exhibit 35: Roche Diagnostics opportunity assessment
Exhibit 36: Myriad Genetics strength assessment
Exhibit 37: Myriad Genetics strategy assessment
Exhibit 38: Myriad Genetics opportunity assessment
Exhibit 39: QIAGEN strength assessment
Exhibit 40: QIAGEN strategy assessment
Exhibit 41: QIAGEN opportunity assessment
Exhibit 42: Thermo Fisher Scientific strength assessment
Exhibit 43: Thermo Fisher Scientific strategy assessment
Exhibit 44: Thermo Fisher Scientific opportunity assessment
Exhibit 45: Bio-Rad Laboratories strength assessment
Exhibit 46: Bio-Rad Laboratories strategy assessment
Exhibit 47: Bio-Rad Laboratories opportunity assessment
Exhibit 48: Other prominent vendors
